Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Michael A. Curran, Welby Montalvo, Hideo Yagita∥ et al. · Proceedings of the National Academy of Sciences · 2010 · 1.9K citations · Full text

Life Sciences, Immunology, Oncology +17

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

Karina Kulangara, Nancy R. Zhang, Ellie Corigliano et al. · Archives of Pathology & Laboratory Medicine · 2018 · 536 citations · Full text

Medicine, Immunology, Oncology +17

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Li Zhang, Yan Huang, Shaodong Hong et al. · The Lancet · 2016 · 525 citations

Medicine, Oncology, Chemotherapy +11

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

Chiun Hsu, Se‐Hoon Lee, Samuel Ejadi et al. · Journal of Clinical Oncology · 2017 · 471 citations

Pharmacy, Oncology, Pharmacotherapy +17

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Wan‐Teck Lim, Boon Cher Goh, Edwin P. Hui et al. · Journal of Clinical Oncology · 2018 · 466 citations · Full text

Medicine, Oncology, Pharmacology +17